Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1990 • ACR Convergence 2020
Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Lylan Bergeron², Samantha Dill², Michelle O'Brien², Laura Vian³, Minal Jain⁴, Manuk Manukyan², Xiaobai Li⁵, Shajia Lu³, Wanxia L. Tsai³, Kalyani Mishra Thakur⁶, Yinghui Shi⁶, Massimo Gadina⁷, April Brundidge², Michelle Millwood², Lisa G. Rider⁸ and Robert Colbert², ¹Juvenile Myositis Pathogenesis and Therapeutics Unit / NIAMS / National Institutes of Health, Bethesda, MD, ²Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ³Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁴Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁵Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, ⁶Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 0457 • ACR Convergence 2020
Improving Pneumococcal Vaccination Rates in Immunosuppressed Rheumatology Patients
Julia Harris¹, Michael Holland², Emily Fox², Amy Ivy³, Maria Ibarra², Cara Hoffart², Jordan Jones², Leslie Favier⁴ and Ashley Cooper², ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, MO, ³Children's Mercy Kansas City, Kansas City, ⁴Children's Mercy Kansas City, Leawood, KS
Background/Purpose: The Centers for Disease Control and Prevention recommends pneumococcal vaccination of high-risk patients, including patients on iatrogenic immunosuppression. Many patients seen in the rheumatology…
Abstract Number: 0727 • ACR Convergence 2020
Hip Involvement Leads to Poor Outcome in Adulthood in Children with Enthesitis Related Arthritis (ERA) Category of Juvenile Idiopathic Arthritis (JIA)
Naveen R¹, Namita Mohindra¹, Neeraj Jain¹ and Amita Aggarwal², ¹Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Enthesitis related arthritis (ERA) is the commonest category of JIA seen in India and constitutes 30-40% of all JIA patients. There are many studies…
Abstract Number: 1160 • ACR Convergence 2020
Treatment Intensity and Impact on Bone Lesion Evolution and Distribution Patterns in Severe Chronic Recurrent Multifocal Osteomyelitis
Aleksander Lenert¹, T. Shawn Sato², Sedat G Kandemirli¹, Patrick Ten Eyck¹ and Polly Ferguson³, ¹University of Iowa, Iowa City, IA, ²University of Iowa, Iowa City, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: To compare bone lesion evolution and bone lesion distribution patterns identified by whole body magnetic resonance imaging (WB-MRI) by treatment intensity in patients with…
Abstract Number: 1250 • ACR Convergence 2020
Early Sjögren Antibodies: Potential Biomarker for Abnormal Minor Labial Salivary Gland Biopsy in Juvenile Sjögren’s Syndrome
Akaluck Thatayatikom¹, Sthorn Thatayatikom¹, Indraneel Bhattacharyya², Melissa Elder¹, Renee Modica¹ and Seunghee Cha², ¹Department of Pediatrics, University of Florida, Gainesville, FL, ²College of Dentistry, University of Florida, Gainesville, FL
Background/Purpose: Juvenile Sjögren’s Syndrome (jSS) is a perplexing systemic autoimmune disease in children presenting with positive autoantibodies, glandular, and/ or extraglandular symptoms. In pediatric practice,…
Abstract Number: 1668 • ACR Convergence 2020
Long-Term Outcomes in Children Born to Anti-Ro and/or Anti-La Positive Mothers
Talia Diaz¹, Daniela Dominguez², Edgar Jaeggi³, Andrea Knight⁴, Carl A. Laskin⁵, Lawrence Ng⁶, Franklin Silverio¹, Earl D. Silverman⁷ and Linda Hiraki⁸, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ³Fetal Cardiac Program, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁵Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, Hospital for Sick Children, Toronto, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada
Background/Purpose: Neonatal Lupus Erythematosus (NLE) is an acquired autoimmune disorder associated with the transplacental passage of maternal anti-Ro and/or anti-La antibodies. Previous studies have suggested…
Abstract Number: 1689 • ACR Convergence 2020
Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada
Abdulrahman Alkanhal¹, Joseph Saunders², Fajer Altammar³, Adam Huber⁴, Andrew Lynk², Alison MacLeod⁵, Oliva Ortiz-Alvarez⁶, Meighan Adams², Suzanne Ramsey⁷, Elizabeth Stringer⁸, Andrew Warren² and Bianca Lang⁹, ¹University of Alberta, Edmonton, AB, Canada, ²Dalhousie University, Halifax, Canada, ³Mcmaster University, Hamilton, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Annapolis Valley Health, Kentville, Canada, ⁶St Martha's Regional Hospital, Antigonish, Canada, ⁷IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ⁸IWK Health Centre, Halifax, NS, Canada, ⁹Dalhousie University - Halifax, Halifax, NS, Canada
Background/Purpose: Kawasaki Disease (KD), a systemic vasculitis of unknown etiology, is now the leading cause of acquired heart disease in children in North America. Its…
Abstract Number: 1991 • ACR Convergence 2020
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq², Mary Buckley³, Kathryn Torok⁴, Barbara Edelheit⁵, Kaleo Ede⁶, Christopher Liu⁷ and C. Egla Rabinovich⁸, ¹Hackensack University Medical Center, Hackensack, ²Montclair State University, Montclair, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Conneticut Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, AZ, ⁷U Pittsburgh, Pittsburgh, ⁸Duke University Hospital, Durham, NC
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: 0471 • ACR Convergence 2020
Splice Site Variants in IKBKG, Encoding NEMO, Detected by a Customized Analysis of Next-Generation Sequencing Data Cause an Early-onset Autoinflammatory Syndrome of Panniculitis and Cytopenias in Male and Female Patients
Adriana de Jesus¹, Sofia Torreggiani², Bin Lin², Jacob Mitchell², Eric Karlins³, Andrew Oler³, Sara Alehashemi⁴, Dana Kahle⁵, Katelin R. Honer², Gema Souto Adeva², Eric Hanson⁶, Gina Montealegre Sanchez⁷, Amer Khojah⁸, Timothy Moran⁹, Eveline Wu⁹, Chris Scott¹⁰, Timothy Ronan Leahy¹¹, Emma Jane MacDermott¹¹, Orla Killeen¹², Thaschawee Arkachaisri¹³, Zoran Gucev¹⁴, Kathryn Phillippi¹⁵, Vafa Mammadova¹⁶, Gulnara Nasrullayeva¹⁶ and Raphaela Goldbach-Mansky¹⁷, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ²Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ³Bioinformatics and Computational Biosciences Branch/NIAID/NIH, Bethesda, MD, ⁴Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, ⁵Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, ⁶Indiana University School of Medicine, Indianapolis, IN, ⁷NIAID/NIH, Rockville, MD, ⁸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹UNC Chapel Hill, Chapel Hill, NC, ¹⁰University of Cape Town, Cape Town, South Africa, ¹¹Our Lady's Children's Hospital, Dublin, Ireland, ¹²National Centre for Paediatric Rheumatology, CHI at Crumlin, Dublin, Ireland, ¹³Duke-NUS Medical School, Singapore, Singapore, ¹⁴University Children's Hospital, Medical Faculty Skopje, Skopje, Macedonia, ¹⁵Akron Children’s Hospital, Akron, OH, ¹⁶Azerbaijan Medical University, Baku, Azerbaijan, ¹⁷Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD
Background/Purpose: The Inhibitor of Kappa-B Kinase Regulatory Subunit Gamma (IKBKG) is located on the X chromosome and encodes the NF-κB essential modulator (NEMO). Loss-of-function mutations…
Abstract Number: 0731 • ACR Convergence 2020
Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U
Jackeline Rodriguez-Smith¹, Virginia Miraldi Utz², Amy Cassedy¹, Sherry Thornton¹, Grant Schulert³, Alyssa Sproles⁴, Najima Mwase¹, Theresa Hennard¹, Mekibib Altaye², Alexei Grom¹ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati
Background/Purpose: The pathogenesis of pediatric uveitis remains unclear. Studies of biomarkers using aqueous humor (AqH) identified S100 proteins, cytokines, and chemokines as potential biomarkers of…
Abstract Number: 1161 • ACR Convergence 2020
Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis
Farzana Nuruzzaman¹, Mingqian Huang², Christian Hedrich³, Hermann Girschick⁴, Julie Cherian⁵, T. Shawn Sato⁶, Karen Onel⁷, Polly Ferguson⁸ and Yongdong Zhao⁹, ¹Stony Brook Children's Hospital, Stony Brook, NY, ²Mount Sinai Hospital, 10003, NY, ³University of Liverpool, Liverpool, United Kingdom, ⁴Vivantes Children’s Hospital, Wuerzburg, Germany, ⁵Stony Brook Children�s Hospital, Stony Brook, NY, ⁶University of Iowa, Iowa City, ⁷Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁸University of Iowa Carver College of Medicine, Iowa City, IA, ⁹University of Washington, Seattle, WA
Background/Purpose: Radiological imaging is integral to the diagnosis of chronic nonbacterial osteomyelitis (CNO) and has been included as a central component in suggested diagnostic criteria…
Abstract Number: 1492 • ACR Convergence 2020
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Report of Primary Study Outcomes
Yukiko Kimura¹, George Tomlinson², Laura Schanberg³, Mary Ellen Riordan⁴, Anne Dennos⁵, Vincent Del Gaizo⁶, Katherine Murphy⁷, Pamela F. Weiss⁸, Brian Feldman⁹ and Sarah Ringold¹⁰, ¹Hackensack Meridian School of Medicine, Hackensack, NJ, ²Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, ³Duke University Medical Center, Durham, NC, ⁴Hackensack University Medical Center, Westwood, NJ, ⁵Duke University, Durham, NC, ⁶Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁷Lousiana Department of Public Health, New Orleans, LA, ⁸Children's Hospital of Philadelphia, Philadelphia, ⁹The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Seattle Children's, Seattle, WA
Background/Purpose: There is uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed…
Abstract Number: 1671 • ACR Convergence 2020
Identifying Rare Genetic Variants in Childhood-onset Monogenic Systemic Lupus Erythematosus
Melissa Misztal¹, Fangming Liao², Sergey Naumenko³, Andrea Knight⁴, Daniela Dominguez⁵, JingJing Cao², Declan Webber⁶, Bhooma Thiruvahindrapuram⁷, Deborah Levy⁶, Andrew Paterson², Earl D. Silverman⁸ and Linda Hiraki⁹, ¹Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Oakville, ON, Canada, ²Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Canada, ³The Centre for Computational Medicine, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ⁸Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada
Background/Purpose: Among children diagnosed with systemic lupus erythematosus (SLE), there exists monogenic forms of SLE, where rare variants in a single gene lead to disease.…
Abstract Number: 1690 • ACR Convergence 2020
Henoch-Schönlein Purpura Nephritis: Different Histological Classifications, but Which One Is Most Strongly Associated to the Outcome of the Disease? Pilot Study of the Paediatric Rheumatology European Society Vasculitis Working Party
Martina Held¹, Mario Sestan¹, Marijana Coric¹, Stela Bulimbasic¹, Teresa Giani², Neil Martin³, Nastasia Cekada¹, Sasa Srsen⁴, Ana Gudelj Gracanin⁵, Domagoj Kifer⁶, Merav Heshin⁷, Angelo Ravelli⁸, Rolando Cimaz⁹, Seza Ozen¹⁰, Alenka Gagro¹¹, Marijan Frkovic¹ and Marija Jelusic¹, ¹University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, ²Anna Meyer Children’s Hospital, Florence, Italy, Florence, Toscana, Italy, ³Royal Hospital for Children, Glasgow, United Kingdom, Glasgow, Scotland, United Kingdom, ⁴University Hospital Centre Split, University of Split School of Medicine, Split, Croatia, Split, Splitsko-Dalmatinska, Croatia, ⁵University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, ⁶Faculty of Pharmacy and Biochemistry, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, ⁷Dana Dwek Children's Hospital, Tel Aviv, Israel, Tel Aviv, Tel Aviv, Israel, ⁸Università degli Studi di Genova, Genoa, Italy, ⁹ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy, ¹⁰Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, ¹¹Children's Hospital Zagreb, Josip Juraj Strossmayer University of Osijek, Medical Faculty Osijek, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia
Background/Purpose: Henoch-Schönlein purpura nephritis (HSPN) is the main and almost the only cause of morbidity and mortality among children suffering from this most common vasculitis…
Abstract Number: 0530 • ACR Convergence 2020
Pediatric APS: Clinical Features, Therapeutic Interventions, and Damage in a Series of 22 Cases
Jacqueline Madison¹, Kelsey Gockman¹ and Jason Knight², ¹University of Michigan, Ann Arbor, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.